American Diabetes Association. (2020). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care, 43(Suppl 1), S98-S110.
DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2019). Pharmacotherapy: A Pathophysiologic Approach (10th ed.). McGraw-Hill Education.
Ndefo, U. A., Anidiobi, N. O., Basheer, E., & Eaton, A. T. (2015). Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes. Pharmacy and Therapeutics, 40(9), 650–659.
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450666/
NHS Greater Glasgow and Clyde. (2020). Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects (SUGAR-DM-HF). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03485092
Empagliflozin: Uses, Interactions, Mechanism of Action. DrugBank (n.d.). DrugBank Online. https://go.drugbank.com/drugs/DB09038
Jardiance - Accessdata.fda.gov. (n.d.). FDA. Retrieved July 18, 2023, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204629s033lbl.pdf